Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 5, 2025Journal of Medicinal Chemistry

Discovery of Highly Selective and Potent Macrocyclic JAK2 Inhibitors for the Treatment of MPNs

View Full Paper
Ask AI
Bookmark
Share

Authors

SQSonghui QinRWRui WuYTYang Tian

Discussion

Loading...

Member takes

Overview

Novel macrocyclic jak2 inhibitors improve selectivity and efficacy in mPN models, implying better treatment outcomes.

Key Points

  • Compound 15au demonstrates potent jak2 inhibition with an IC50 of 2 nM, showing significant therapeutic promise.
  • Inhibition results in enhanced kinase selectivity, boasting 89.5-fold selectivity over jak1, improving treatment targeting.
  • The macrocyclization strategy effectively refines jak2 inhibitors, enhancing metabolic stability and overall efficacy.
  • 15au outperforms existing therapies like pacritinib at lower doses, indicating potential clinical advantages for mPN treatment.

Cite This Study

Qin et al. (2025) studied this question.

synapsesocial.com/papers/689522009f4f1c896c428ec8https://doi.org/10.1021/acs.jmedchem.5c01686
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Discovery of a highly selective JAK2 inhibitor with a furopyrimidine scaffold2026
  2. 2Discovery of JAK2V617F mutant specific allosteric inhibitors for the treatment of myeloproliferative neoplasms2025 · 2 citations
  3. 3Identification of novel, potent, and selective JAK2V617F inhibitors2025 · 1 citations
  4. 4Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity2024 · 32 citations
  5. 5Designing JAK2 Inhibitors Beyond Myeloproliferative Neoplasms ‐ Theoretical and Experimental Analysis for Solid Cancers2024